Vedanta Biosciences
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
$60MGrowth
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
Developing native human monoclonal antibodies to treat intractable infectious diseases
Develops immunotherapeutic treatments for antimicrobial infections